Abbvie and Allergan have entered into a consent decree agreement with the staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie’s acquisition of Allergan. Under the terms of the consent decree, the companies have agreed to divest brazikumab, an investigational inhibitor in the development for autoimmune diseases, to AstraZeneca, and Zenpep, a treatment for exocrine pancreatic insufficiency, to Nestlé. Nestlé will also acquire Viokace, another pancreatic enzyme preparation. The consent decree remains subject to further review and approval by the commissioners of the FTC. The parties anticipate closing in May 2020.